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Abstract
Delta-like ligand 4 (Dll4) expressed in tumor cells plays a key role to promote tumor growth of 
numerous cancer types. Based on a novel antihuman Dll4 monoclonal antibody (61B), we 
developed a 64Cu-labeled probe for positron emission tomography (PET) imaging of tumor Dll4 
expression. In this study, 61B was conjugated with the 64Cu-chelator DOTA through lysine on the 
antibody. Human IgG (hIgG)-DOTA, which did not bind to Dll4, was also prepared as a control. 
The Dll4 binding activity of the probes was evaluated through the bead-based binding assay with 
Dll4-alkaline phosphatase. The resulting PET probes were evaluated in U87MG glioblastoma and 
HT29 colorectal cancer xenografts in athymic nude mice. Our results demonstrated that the 61B-
DOTA retained (77.2 ± 3.7) % Dll4 binding activity of the unmodified 61B, which is significantly 
higher than that of hIgG-DOTA (0.06 ± 0.03) %. Confocal microscopy analysis confirmed that 
61B-Cy5.5, but not IgG-Cy5.5, predominantly located within the U87MG and HT29 cells 
cytoplasm. U87MG cells showed higher 61B-Cy5.5 binding as compared to HT29 cells. In 
U87MG xenografts, 61B-DOTA-64Cu demonstrated remarkable tumor accumulation (10.5 ± 1.7 
and 10.2 ± 1.2%ID/g at 24 and 48 h postinjection, respectively). In HT29 xenografts, tumor 
accumulation of 61B-DOTA-64Cu was significantly lower than that of U87MG (7.3 ± 1.3 and 6.6 
± 1.3%ID/g at 24 and 48 h postinjection, respectively). The tumor accumulation of 61B-
DOTA-64Cu was significantly higher than that of hIgG-DOTA-64Cu in both xenografts models. 
Immunofluorescence staining of the tumor tissues further confirmed that tumor accumulation of 
61B-Cy5.5 was correlated well with in vivo PET imaging data using 61B-DOTA-64Cu. In 
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conclusion, 61B-DOTA-64Cu PET probe was successfully synthesized and demonstrated 
prominent tumor uptake by targeting Dll4. 61B-DOTA-64Cu has great potential to be used for 
noninvasive Dll4 imaging, which could be valuable for tumor detection, Dll4 expression level 
evaluation, and Dll4-based treatment monitoring.
Graphical abstract
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Introduction
The Notch family of proteins is composed of four transmembrane receptors (Notch 1, 2, 3, 
and 4), which are activated by five known membrane-anchored ligands (jagged 1 and 2 and 
delta-like ligand Dll1, 3, and 4).1 Among these, Dll4 has recently appeared as a critical 
regulator of tumor angiogenesis. When expressed in tumor cells, Dll4 was found to activate 
Notch signaling, increase blood vessel size, and improve tumor vascular function in various 
cancer types.2
Based on its important role in cancer progression, Dll4 targeted therapy became a promising 
treatment strategy for patient management. Emerging evidence suggested that the blockage 
of Dll4 led to broad spectrum antitumor activity in cancer cell line-based xenograft 
models.3–5 For example, soluble forms of Dll4 interrupted Dll4-Notch signaling pathway 
and led to decreased tumor growth.3 More importantly, Dll4 overexpression was suggested 
to be an independent predictor of poor survival in malignant tumor.3 Combination therapy 
with Dll4 antibody and ionizing radiation or ultrasound-stimulated microbubbles resulted in 
extensive tumor necrosis and enhanced tumor growth delay in mice xenografts.6,7 
Combining Dll4-targeted siRNA with bevacizumab also resulted in greater inhibition of 
tumor growth.8 Despite the encouraging results, not all the patients will benefit from Dll4-
tagreted therapy due to heterogeneous Dll4 expression levels; in addition, the Dll4 
expression level may change during such targeted therapy, which may affect therapeutic 
efficacy and require the adjustment of treatment regime. Therefore, quantitative analysis of 
Dll4 expression in living subjects may greatly facilitate patient selection and treatment 
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response monitoring. Despite the critical need, research on robust, quantitative, and 
noninvasive imaging methods to visualize Dll4 expression in vivo are still very limited.9
Positron emission tomography (PET) is a highly sensitive, noninvasive, and quantitative 
technique that has been used widely for imaging biomarker distribution, concentration, and 
functions in vivo under normal and pathological conditions. In this study, we aimed to 
develop a 64Cu labeled humanized monoclonal Dll4 antibody (61B) for human Dll4 
imaging. We used two cancer xenograft models to investigate Dll4 expression using PET 
imaging with the newly developed probe. The resulting PET probe may provide important 
information on determining the utility of Dll4-targeted chemo- and radiotherapy by selecting 
the Dll4 positive patients.
Experimental Section
Materials
The antibody 61B and Dll4-alkaline phosphatase (Dll4-AP) were kindly provided by 
Vasgene Therapeutics Inc. (Los Angeles, CA, USA). 1,4,7,10-Tetra-azacyclododecane-N,N
′,N″,N‴-tetraacetic acid (DOTA) was purchased from Macrocyclics Inc. (Dallas, TX, 
USA). PD-10 disposable columns were purchased from GE Healthcare Life Sciences 
(Piscataway, NJ, USA). Ultra Protein A Resin for binding activity assay was purchased from 
GenScript USA Inc. (Piscataway, NJ, USA). Human IgG (hIgG) was purchased from 
Rockland (Gilbertsville, PA, USA).
For immunofluorescence staining, rat antimouse CD31 antibody was purchased from Abcam 
(Cambridge, MA, USA). Secondary antibody Alexa Fluor 568 Goat Anti-Rat IgG was 
purchased from Life Technologies (Grand Island, NY, USA). Cy5.5 N-hydroxysuccinimide 
(Cy5.5-NHS) ester was purchased from Lumiprobe Corporation (Hallandale Beach, Florida, 
USA). 64Cu was produced using the 64Ni(p,n)64Cu nuclear reaction in Washington 
University and the University of Wisconsin and supplied in high specific activity as 64CuCl2 
in 0.1 N HCl.
Chemistry and Radiochemistry
61B and hIgG were conjugated with DOTA using a method published previously.10 Briefly, 
DOTA was first activated to DOTA-N-hydroxysulfo-succinimidyl as reported 
previously.10,11 After cooled to 4 °C, the reaction mixture was added to 61B or hIgG in 0.1 
M borate buffer (pH 8.5) and incubated at 4 °C overnight. The 61B-DOTA or hIgG-DOTA 
was purified using a PD-10 column and concentrated by a Centricon filter (Millipore). The 
concentrations of 61B-DOTA or hIgG-DOTA were measured based on absorbance at 280 
nm using unconjugated antibody of known concentrations as a standard. The synthesis of 
61B-DOTA-64Cu and hIgG-DOTA-64Cu was performed following procedures described 
previously.10 Briefly, 30 μg of the 61B-DOTA-64Cu or hIgG-DOTA-64Cu was loaded 
to 64CuCl2 (37MBq 64Cu per 30 μg antibody). The pH of the reaction mixture was adjusted 
to 5.5 with 0.1 N acetate buffer and incubated at 40 °C for 1 h with constant shaking. The 
61B-DOTA-64Cu or hIgG-DOTA-64Cu was purified by a PD-10 column. The radioactive 
fraction containing 61B-DOTA-64Cu or hIgG-DOTA-64Cu product was collected for further 
Zhou et al. Page 3













experiments. Twenty micro curie of 64Cu-labeled product was loaded onto Centricon with a 
molecular weight cutoff of 10 000. After initial centrifugation, 0.5 mL of PBS buffer was 
added followed by additional centrifugation. After final wash, the fraction on top of the 
centricon (with MW > 10 000 containing 61B-DOTA-64Cu) was collected, and the 
radioactivity in this fraction was measured using γ-counter. The purity of 61B-DOTA-64Cu 
was calculated by dividing 61B-DOTA-64Cu associated radioactivity (after centrifugation) 
with 20 uCi (total product). In addition, 10 μg of 61B-DOTA-64Cu was analyzed by 4–12% 
NuPAGE Bis-Tris gel. Two gels were run in parallel. After electrophoresis, one gel was 
stained with SimplyBlue SafeStain for protein purity assessment, and the other gel was 
analyzed by autoradiography for radioactivity measurement. The radiochemical purity of the 
final product was further confirmed by comparing these two measurements.
Binding Affinity Assay
To test the Dll4 binding activity of antibody conjugates, 300 ng of Dll4-alkaline phosphatase 
(AP) was preincubated with 0, 10, 20, 40, 80, or 120 ng of unmodified 61B antibody for 15 
min. The formed complex was then immobilized on Protein A Resin (10 μL per tube) for 1 
h. Unbound proteins were removed by washing twice with PBS, and precipitated AP activity 
(OD405 nm value) was detected on microplate reader after adding para-nitro-phenylphosphate 
(PNPP). A standard curve and formula were derived based on OD405 nm values and 61B 
concentrations.12 To determine Dll4 binding affinity of DOTA-conjugated antibodies, 50 ng 
of hIgG-DOTA or 61B-DOTA immobilized on Protein A Resin (10 μL per tube) was 
incubated with 300 ng of Dll4-AP for 1 h. Unbound proteins were removed by washing 
twice with PBS. The amount of DOTA-conjugates of antibody, which can actively bind to 
Dll4, was then determined after adding PNPP and calculated according to the formula 
developed above. Binding activities of DOTA-conjugated antibodies were expressed as the 
percentage of active 61B-DOTA (equivalent to ng of unmodified 61B) to the total amount of 
61B-DOTA. Binding activity of hIgG-DOTA was also calculated accordingly. Each sample 
was repeated as triplicate.
Synthesis of 61B-Cy5.5 and hIgG-Cy5.5
An aqueous solution of 61B or hIgG (350 μg) was mixed with Cy5.5-NHS in 0.1 M borate 
buffer (pH 8.5). The molar ratio of antibody to Cy5.5-NHS was 1 to 2.4. After incubated 
overnight at 4 °C, the reaction mixture was passed through a PD-10 column and eluted with 
PBS solution.13 61B-Cy5.5 or hIgG-Cy5.5 was collected; the absorbance at 280 and 673 nm 
of 61B-Cy5.5 and hIgG-Cy5.5 were measured with Thermo BioMate 3S spectrophotometers 
(Thermo Fisher Scientific Inc., Waltham, MA, USA). The dye-to-antibody molar ratio was 
calculated according to manufacturer's instructions.
Cell Culture and Animal Models
Animal procedures were performed according to protocol approved by the University of 
North Carolina Institutional Animal Care and Use Committee. Human colorectal cancer cell 
line HT29 and human glioblastoma cell line U87MG were obtained from American Type 
Culture Collection (Manassas, VA, USA) and were cultured in RPMI-1640 or DMEM 
(Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS) (Omega 
Scientific, Tarzana, CA, USA), respectively. The cells were maintained at 37 °C in a 
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humidified atmosphere containing 5% CO2. Tumor models were established in 4- to 6-week 
old female athymic nude mice (Harlan, Indianapolis, IN, USA). The 2 × 106 tumor cells 
suspended in 100 μL of cell culture medium without FBS were inoculated subcutaneously at 
the right shoulder. The mice were used for microPET imaging studies when the tumor 
reached about 0.8 cm in diameter (3–4 weeks after cancer cells inoculation).
Tumor Cell Confocal Microscopy Analysis
To test the cell binding with 61B, 5 × 104 U87MG or HT29 cells were seeded in each 
chamber of an eight-chamber slide (Thermo Fisher Scientific Inc., Waltham, MA, USA) and 
incubated overnight to allow cell adhesion. After the cells were rinsed with PBS buffer 
twice, 300 μL of complete culture medium containing 60 nM 61B-Cy5.5 or hIgG-Cy5.5 was 
added. The cells were incubated for 30 min at 37 °C, followed by PBS buffer washing, and 
fixed in 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA, USA) for 20 
min at room temperature. Subsequently, the cells were covered with EverBrite Mounting 
Medium with 4,6-diamino-2-phenylindole (DAPI, Biotium, CA, USA) and observed under 
Zeiss LSM 710 laser scanning microscope (Zeiss, Jena, German).
MicroPET Imaging
MicroPET scans were performed as described previously.11,14 About 3.7–7.4MBq dose of 
PET probe (61B-DOTA-64Cu) was intravenously injected into each mouse under isoflurane 
anesthesia (2–4% for induction and 2% for maintenance in 100% O2). Static scans were 
acquired at 1, 24, 48, and 72 h after injection. The images were reconstructed by two-
dimensional ordered-subsets expectation maximum. For each microPET scan, regions of 
interest were drawn over the tumor and major organs on decay-corrected whole-body 
coronal images. The radioactivity accumulation within tumors or organs was obtained from 
the mean value within the multiple regions of interest and then converted to percentage 
injected dose per gram (%ID/g).15 For both HT29 and U87MG tumor models, hIgG-
DOTA-64Cu was used as the control to confirm the receptor specificity of 64Cu-labeled 61B. 
The tumors of each group (n = 4) were size-matched. After all PET scans were performed, 
the animals were sacrificed; the blood, heart, and other major organs were collected and wet-
weighed. The radioactivity in the tissue was measured using a gamma-counter (Packard 
Instruments). The results are presented as the percentage injected dose per gram of tissue 
(%ID/g). Values are expressed as the means ± SD for a group of three animals.
Immunofluorescence Staining of Tumor Tissue
To investigate the antibody distribution within tumor tissues, 61B-Cy5.5 or hIgG-Cy5.5 (0.2 
nmol) was injected into each mice bearing U87MG or HT29 tumor via tail vein. At 48 h 
after injection, the mice were euthanized, and the tumors were dissected, embedded in 
Tissue-Tec optimal-cutting-temperature compound (Sakura Finetek, Torrance, CA, USA) 
and cut into 8 μm sections. Frozen sections were fixed in ice-cold acetone for 5 min, blocked 
with 10% normal horse serum (Gibco, Grand Island, NY, USA) for 20 min, and then 
incubated with primary anti-CD31 antibody at room temperature for 30 min. After PBS 
buffer washing, the sections were incubated with secondary antibody for 30 min at room 
temperature. Subsequently, the slides were covered with EverBrite Mounting Medium 
containing DAPI and observed under Zeiss LSM 710 laser scanning microscope.
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Quantitative data are expressed as mean ± SD. Means were compared using one-way 
ANOVA and the Student's t test. p values less than 0.05 were considered statistically 
significant.
Results
Chemistry, Radiochemistry, and Binding Activity Assay
61B and hIgG were conjugated with 64Cu chelator DOTA through amino groups. The 
resultant 61B-DOTA and hIgG-DOTA were labeled with 64Cu as described. The 
radiochemical yields were 65.6% and 53.4% for 61B-DOTA-64Cu and hIgG-DOTA-64Cu, 
respectively. Based on centrifugation experiment, 99.8% of radioactivity in final labeling 
product was associated with 61B-DOTA-64Cu; and the free 64Cu was only 0.2% of the final 
product. In addition, 10 μg of 61B-DOTA-64Cu gave a single band on NuPAGE gel with 
approximate molecular weight of 150 kDa; and this signal was well-associated with most of 
the radioactivity detected by autoradiography (Supplementary Figure 2). These results 
further confirmed that 61B antibody integrity was retained during DOTA conjugation 
and 64Cu labeling, and the 61B-DOTA-64Cu has high radiochemical purity after purification. 
The calculated specific activity of 61B-DOTA-64Cu and hIgG-DOTA-64Cu were 121 and 98 
MBq/μmol, respectively. To study the impact of DOTA-conjugation on Dll4 binding ability, 
a binding affinity assay was performed. Based on OD405 nm values and 61B concentrations, 
Formula 1 was derived. Compared with unlabeled 61B, 61B-DOTA retained (77.2 ± 3.7) % 
of Dll4 binding ability; while hIgG-DOTA only had background level of Dll4 binding ability 
((0.06 ± 0.03) %, Figure 1).
(1)
61B-Cy5.5 and hIgG-Cy5.5 were synthesized through the modification of amino groups. 
Based on the absorbance at 280 and 673 nm, the molar ratio of dye/61B and dye/hIgG was 
calculated to be 3.7 and 4.8, respectively.
Dll4 Binding with Tumor Cell Lines
Dll4 binding with U87MG and HT29 cell lines were analyzed by cell confocal microscopy 
image. As shown in Figure 2, intracellular fluorescence was observed in both U87MG and 
HT29 tumor cells incubated with 61B-Cy5.5; and U87MG cells showed higher fluorescence 
signal intensity as compared to HT29. However, no fluorescent signal was observed in IgG-
Cy5.5 treated cells. In addition, binding of fluorescence labeled 61B can be successfully 
blocked by added access amount of nonlabeled 61B antibody (Supplementary Figure 6). 
Since 61B-Cy5.5 showed specific binding to both U87MG and HT29, both tumor xenografts 
were established and used for in vivo evaluation of 61B-DOTA-64Cu.
Zhou et al. Page 6














The tumor targeting efficacy of 61B-DOTA-64Cu was evaluated by multiple-time-point static 
MicroPET scans in U87MG and HT29 tumor-bearing mice. hIgG-DOTA-64Cu was used as 
control (n = 4 per group). After intravenous injection of 61B-DOTA-64Cu, both U87MG and 
HT29 tumor xenografts can be clearly visualized with good tumor-to-background contrast 
(Figure 3). The quantitative PET results were shown in Figure 4. For U87MG tumor, the 
uptake was 3.0 ± 0.6, 10.5 ± 1.7, and 10.2 ± 1.2%ID/g, at 1, 24, and 48 h after injection, 
respectively. For HT29 tumor, the uptake was 2.3 ± 0.3, 7.3 ± 1.3, and 6.6 ± 1.3%ID/g at 1, 
24, and 48 h after injection, respectively. The U87MG tumor uptake of the probe was 
significantly higher than HT29 tumor at 24 and 48 h postinjection time points examined (p < 
0.05, Figure 5A). Moreover, the tumor uptakes of hIgG-DOTA-64Cu were significantly 
lower than that of 61B-DOTA-64Cu at 24 and 48 h postinjection in both tumor models (p < 
0.05, Figure 5B,C). At the first time points, both 61B-DOTA-64Cu and hIgG-DOTA-64Cu 
demonstrated high blood pool accumulation in two tumor models, which could be explained 
by the relative long circulation half-life of antibodies in vivo. At 24 h postinjection, the 
activity accumulation in blood pool decreased dramatically. The liver also showed relatively 
high uptake of both 61B-DOTA-64Cu and hIgG-DOTA-64Cu as a result of nonspecific 
uptake through the liver reticular-endothelial system. Muscle uptakes of both 61B-
DOTA-64Cu and hIgG-DOTA-64Cu were minimal and not significantly different at all tested 
time points (Figure 4 and Supplementary Figure 4). In order to further validate the PET 
quantification, biodistribution by direct tissue sampling was obtained right after PET scans 
at 72 h postinjection (Supplementary Figure 3). The U87MG tumor uptake for 61B-
DOTA-64Cu and hIgG-DOTA-64Cu was 8.1 ± 1.8 and 4.5 ± 1.4%ID/g, respectively. In 
contrast, uptake for other normal organs between 61B-DOTA-64Cu and hIgG-DOTA-64Cu 
showed similar results with no significant difference (p > 0.05) (Supplementary Table 1). 
The biodistribution results are consistent with PET quantification.
Immunofluorescence Staining of Tumor Tissues
To investigate the distribution of 61B or IgG within the tumor, tumor tissues were collected 
at 48 h after intravenous injection of 61B-Cy5.5 or IgG-Cy5.5. Frozen sections of tumors 
were stained for blood vessels with anti-CD31 antibody. As shown in Figure 6, the 
accumulation of 61B-Cy5.5 in the U87MG tumor tissues was significantly higher than that 
in HT29 tumor tissues. In addition, the distribution of 61B-Cy5.5 in HT29 tumor tissue was 
more proximate to CD31 positive tumor vessels. No significant distribution of hIgG-Cy5.5 
was observed in either U87MG or HT29 tumor models. Both in vivo PET imaging data and 
in vitro data indicated that 61B could specifically and effectively bind to Dll4 expressed in 
the tumor models tested, especially in U87MG.
Discussion
Accumulating evidence indicates that Dll4 is a promising target for diagnosis, prognosis, 
and therapy in numerous cancer types.8,16–18 Therefore, the ability to noninvasively 
visualize Dll4 expression in vivo could be of great clinical value in Dll4 based tumor 
management. For example, through noninvasive Dll4-targeted imaging, the expression of 
Dll4 can be assessed conveniently, and the changes of Dll4 expression during treatment 
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could be monitored. Obviously, these would aid in many procedures, including early lesion 
detection, prognostic evaluation, patient selection, better treatment monitoring, and dose 
optimization.19
Previously, the soluble forms of Dll4 or Dll4-Fc (sDll4 or sDll4-Fc) were used as the agent 
for Dll4-Notch pathway blocking.3,20 However, both the tumor uptake and the 
pharmacokinetics of these probes need to be further improved. Furthermore, sDll4 or sDll4-
Fc will inhibit the binding of all Notch and Notch ligands, including Dll1, Dll4, Jagged1, 
and Jagged2, which may introduce unwanted side effects. Monoclonal antibody is 
considered as potentially the most specific probe for imaging because it offers an unmatched 
ability to bind selectively to the target of interest.21 Recently, anti-Dll4 antibodies have been 
used for Dll4-Notch pathway target management.22–24 Due to the high binding activity and 
specificity, the antibody-based imaging probes would be more suitable for patient screening 
as they are closely related to the antibody drug to be used in therapy. In this study, we 
developed Dll4-targeted PET probes based on anti-Dll4 monoclonal antibodies. In our 
approach, a novel 64Cu-labeled Dll4 antibody, 61B-DOTA-64Cu, was synthesized and 
characterized. Binding activity assay showed that 61B-DOTA preserved (77.2 ± 3.7) % Dll4 
binding activity as compared with unlabeled 61B. 61B-Cy5.5 was also synthesized, which 
can effectively bind to Dll4 positive U87MG and HT29 cells. Confocal laser scanning 
microscope imaging indicated that the antibody was mainly observed in the cytoplasm, 
which indicated that the antibody may get internalized upon binding to Dll4. Although the 
mechanism of internalization needs further investigation, it could be caused by Dll4-
mediated endocytosis.25 In contrast, hIgG-Cy5.5 showed almost no binding to both tumor 
cell lines. These evidence suggested that 61B could specifically bind to both U87MG and 
HT29 tumor cells.
We further tested Dll4 targeting efficacy of 61B-DOTA-64Cu in U87MG and HT29 tumor 
bearing mice with microPET imaging. In both xenografts models, tumor uptake of 61B-
DOTA-64Cu increased with time, peaked at 24 h postinjection, and maintained at a relatively 
high level until 48 h postinjection. At 24 and 48 h postinjection, the tumor uptake was stable 
in U87MG model, but decreased slightly over time in HT29 tumor model. Furthermore, the 
probe uptake in U87MG tumor was significantly higher than that in HT29 tumor at 24 and 
48 h postinjection. Both active uptake (as a result of Dll4-Notch interaction) and passive 
uptake (as a result of the enhanced permeability and retention effect) contributed to the 
probe accumulation in tumors. Because the IgG tumor uptake for U87MG and HT29 are 
comparable, the tumor uptake difference between U87MG and HT29 should be mainly 
caused by active targeting. As shown in Figure 2, U87MG tumor cell demonstrated stronger 
binding toward 61B-Cy5.5 compared with HT29 cell. Nonetheless, additional quantitative 
analysis needs to be performed to further confirm the cell surface Dll4 expression in these 
cell lines. Due to the limited availability of the antibody, blocking experiment with 61B was 
not performed in this study. In order to measure the specific targeting attributed to 61B 
antibody, hIgG-DOTA-64Cu was used as the control. With a lack of active targeting 
capability, tumor accumulation of hIgG-DOTA-64Cu represents passive uptake. As expected, 
the uptake of hIgG-DOTA-64Cu at most time points examined was comparatively low in 
both tumor models, which confirms the target specificity of 61B-DOTA-64Cu. To further 
validate the in vivo findings, we performed tumor tissue immunofluorescence staining of the 
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U87MG and HT29 tumor models at 48 h postinjection of 61B-Cy5.5 or hIgG-Cy5.5, 
respectively. The results clearly demonstrated that more 61B-Cy5.5 accumulated in U87MG 
tumor than in HT29 tumor. There was no significant distribution of hIgG-Cy5.5 in both 
tumor models. These results are consistent with in vivo microPET imaging studies. 
Interestingly, we also noticed that the 61B-Cy5.5 distribution in HT29 tumor tissue 
coincided with CD31 positive blood vessel distribution (Figure 6 and Supplementary Figure 
5). According to the cell staining and in vivo imaging results, the 61B uptake in HT29 tumor 
cell was lower than that in U87MG tumor cell. 61B-Cy5.5 just distributed near the vessels in 
HT29 tumor model maybe because the antibody reaches this area. We do like to point out 
that 61B is the monoclonal antibody of human Dll4, which does not target murine Dll4 that 
may also be overexpressed on vasculature in xenograft mouse model. However, clinical 
application of Dll4/Notch pathway block treatment may not be limited to cancer cells that 
overexpress Dll4. Patients could benefit from this treatment if the tumor vasculature is Dll4 
positive. Clearly, PET imaging could play an important role in the patient's selection. From 
another point of view, 61B-DOTA-64Cu might show higher tumor uptake in future clinic 
applications because it recognizes both tumor cells and vasculature associated Dll4 
expression. Accordingly, we believe that the antibody could be used in not only diagnosis 
but also theranostics by conjugated with radionuclides suitable for imaging and therapy 
(e.g., 90Y, 177Lu, or 161Tb).26
Despite the success of this experimental in vitro and in vivo imaging study, there are still 
several open questions remaining to be addressed in the future work. First, the tumors also 
showed some uptake of hIgG-DOTA-64Cu due to the presence of nonspecific accumulation. 
Therefore, the accumulation caused by “passive” targeting needs to be considered during 
data interpretation. Second, because of the relative large molecular size, the antibody usually 
takes longer time to optimally accrete in tumors.27 Various antibody fragments with smaller 
molecular size have been developed, such as diabodies, minibodies, and some antibodies 
based on nontraditional scaffolds.21,28,29 These ligands might offer other alternatives for 
Dll4 targeted tumor imaging in future clinical application. And last, although we have 
demonstrated that the expression level of Dll4 was higher in U87MG cells than in HT29 
cells, we failed to detect the desired 75–80 kDa band corresponding to human Dll4 using 
commercial available rabbit antihuman Dll4 antibody by Western blot. We also tried to using 
61B to probe Dll4 in cell lysate. However, the nonspecific binding was dominant due to the 
fact that 61B is a humanized antibody and HRP labeled antihuman secondary antibody 
needs to be used for membrane development. Clearly, Western blot analysis of Dll4 in 
human glioma U87MG and colorectal cancer HT29 cell lines will need to be further 
optimized using other antibodies. We will try antibodies from other vendors in our follow-up 
studies.
Conclusion
We have described the in vitro and in vivo distribution of 64Cu labeled Dll4 antibody in 
glioblastoma and colorectal cancer models. This approach would be valuable for tumor 
detecting, evaluating the Dll4 expression, and monitoring the Dll4-based cancer therapies. 
Moreover, the newly developed probe might also have potential applications in other cancer 
types expressing Dll4.
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DMEM Dulbecco's minimum essential medium
PBS phosphate buffered saline
NHS N-hydroxysuccinimide
FBS fetal bovine serum
DAPI 4,6-diamino-2-phenylindole
sDll4 soluble forms of Dll4
%ID/g percentage injected dose per gram
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Standard curve and mathematical formula of binding activity.
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Confocal analysis of the antibody distribution in U87MG and HT29 cells. The cells were 
incubated with 61B-Cy5.5 or hIgG-Cy5.5 at 37 °C for 30 min. Images were obtained under 
identical conditions and displayed at the same magnification (×630). Scale bar = 20 μm.
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Decay-corrected whole-body coronal small-animal PET images from static scans at 1, 24, 
and 48 h postinjection of (A) 61B-DOTA-64Cu into U87MG tumor model, (B) 61B-
DOTA-64Cu into HT29 tumor model, (C) hIgG-DOTA-64Cu into U87MG tumor model, and 
(D) hIgG-DOTA-64Cu into HT29 tumor model. Tumors are indicated by white arrows.
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Tumor and major organ radioactivity accumulation quantification from a static scan at 1, 24, 
and 48 h postinjection of (A) 61B-DOTA-64Cu into U87MG tumor model, (B) 61B-
DOTA-64Cu into HT29 tumor model, (C) hIgG-DOTA-64Cu into U87MG tumor model, and 
(D) hIgG-DOTA-64Cu into HT29 tumor model. Data are expressed as average ± SD.
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Time course of tumor uptake from 1 to 48 h postinjection. (A) U87MG and HT29 tumor 
uptake of 61B-DOTA-64Cu. (B) U87MG tumor uptake of 61B-DOTA-64Cu and hIgG-
DOTA-64Cu. (C) HT29 tumor uptake of 61B-DOTA-64Cu and hIgG-DOTA-64Cu. Data are 
expressed as average ± SD, and the p value was calculated with Student's t test (*p < 0.05).
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Confocal fluorescence of 61B-Cy5.5 and immunofluorescence staining of CD31 in U87MG 
and HT29 tumor tissues. Arrows indicated the blood vessels. Images were obtained under 
identical conditions and displayed at the same magnification (×200). Scale bar = 100 μm.
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